WebDoctor Encyclopedia

Childhood Soft-tissue sarcomas

Infantile fibrosarcoma

Infantile fibrosarcoma is a rare, fast-growing soft-tissue tumour of babies, often present at birth on an arm or leg. Most carry an ETV6-NTRK3 fusion, rarely spread and respond well to surgery, larotrectinib or mild chemotherapy.

Medically reviewed Last reviewed October 19, 2026

What is infantile fibrosarcoma?

Infantile fibrosarcoma (IFS) is a rare soft-tissue tumour of babies and very young children. It grows from fibroblasts, the cells that make connective tissue such as the tissue around muscles and under the skin.

Among babies under one year old, no soft-tissue sarcoma is diagnosed more often than IFS. Many cases are present at birth, and some are seen on ultrasound scans during pregnancy. For this reason it is also called congenital fibrosarcoma.

The tumour can grow very quickly and become large, often in an arm or leg. Despite this, it rarely spreads to other parts of the body, and the outlook is very good. Most children are cured (Orbach et al., 2010).

Most IFS tumours carry a gene fusion called ETV6::NTRK3 (Knezevich et al., 1998a). Drugs that block the TRK protein, such as larotrectinib, have transformed treatment, often shrinking the tumour without the need for chemotherapy or large operations (Orbach et al., 2020).

1. Key facts at a glance

Feature Details
Type of tumour Soft-tissue sarcoma of fibroblasts; intermediate, rarely metastasising
How common Rare overall, yet the leading soft-tissue sarcoma in babies under 12 months
Typical age Present at birth or in the first year; almost all under 2 years
Main sites Arms and legs (especially hands and feet), trunk, head and neck
Key signs A fast-growing lump, often red or purple and shiny
Gene change ETV6::NTRK3 fusion in most; other kinase fusions in some
Main treatment Surgery, TRK inhibitors such as larotrectinib, or mild chemotherapy
Outlook Excellent; about 9 in 10 children survive long term
Type Notes
Classic IFS with ETV6::NTRK3 The most common form
IFS-like tumours with other fusions NTRK1, NTRK2, BRAF, MET, RAF1 and others; similar behaviour (Davis et al., 2022)
Cellular congenital mesoblastic nephroma A kidney tumour of babies with the same ETV6::NTRK3 fusion; a close relative of IFS (Knezevich et al., 1998b)
Adult-type fibrosarcoma A different, more aggressive cancer of older children and adults

3. Causes and risk factors

IFS is caused by a gene fusion that forms in the tumour cells during development in the womb or shortly after birth. In most cases, part of the ETV6 gene on chromosome 12 joins part of the NTRK3 gene on chromosome 15.

The resulting fusion protein acts like a switch stuck in the “on” position, sending constant growth signals to the cell.

Question Answer
Is it inherited? No; the fusion occurs only in the tumour cells
Did anything in pregnancy cause it? No known cause in pregnancy has been found
Will brothers or sisters get it? The risk is not increased
Is it infectious? No

Parents often ask whether they could have prevented the tumour. The answer is no: IFS is not caused by anything parents did or did not do.

4. How does it look

On the skin

Feature Description
Size Often large for the baby’s size; can be over 10 cm
Colour Skin over the lump may be red, purple or bluish
Surface Shiny and stretched, with visible veins
Feel Firm, rubbery and usually painless
Ulceration Large tumours may break down and bleed
Growth Can grow noticeably within days or weeks

Because of its colour and blood vessels, IFS is often mistaken for a haemangioma or a vascular malformation at first.

Before birth

On a prenatal ultrasound, IFS may appear as a solid mass on a limb or the trunk. Large tumours can sometimes cause excess amniotic fluid or problems during delivery.

On scans after birth

Scan Findings
Ultrasound Solid mass with many blood vessels
MRI Shows the size of the tumour and its relation to muscles, bones, nerves and blood vessels
CT of the chest Checks for rare spread to the lungs

Under the microscope

IFS is made of densely packed spindle-shaped cells arranged in bundles, sometimes in a herringbone pattern. There are often many dividing cells and blood vessels.

Despite this busy appearance, the tumour behaves far better than an adult fibrosarcoma. Testing for the ETV6::NTRK3 fusion or a pan-TRK stain confirms the diagnosis.

5. Symptoms

Babies with IFS are often otherwise well. The main sign is the lump itself.

Common signs and symptoms

  • A lump or swelling on an arm, leg, hand, foot, trunk or head
  • Rapid growth of the lump
  • Red, purple or shiny skin over the lump
  • Bleeding from the surface of a large tumour
  • Reduced movement of the affected limb

Possible complications

Complication Signs
Bleeding and anaemia Paleness, tiredness, poor feeding
Low platelets and clotting problems Bruising or bleeding in some large tumours
Pressure on nearby organs Breathing or feeding difficulties with head, neck or chest tumours
Heart strain Very large tumours with many blood vessels can, rarely, cause heart failure

When to seek medical advice

See a doctor promptly if a baby has a lump that is growing, especially if it is firm or the skin over it is red, purple or shiny.

Seek urgent help if the lump is bleeding, or if the baby is pale, breathing fast or not feeding.

6. Diagnosis

Test Purpose
Physical examination Assesses the lump and the baby’s general health
Ultrasound First scan; shows a solid mass with blood flow
MRI Plans treatment by showing the tumour’s extent
Biopsy Essential to confirm the diagnosis
Pan-TRK staining and molecular testing Confirm the NTRK fusion or another kinase fusion
Chest CT Checks for rare lung spread
Blood tests Blood count and clotting tests, especially if the tumour is bleeding

Conditions that can look similar

Condition How it differs
Infantile haemangioma A benign blood vessel tumour; usually appears after birth and responds to propranolol
Congenital haemangioma Present at birth; vascular on scans; different biopsy findings
Kaposiform haemangioendothelioma Vascular tumour often with very low platelets
Rhabdomyosarcoma A different sarcoma with muscle markers
Infantile myofibromatosis Benign tumours of myofibroblasts; may be multiple

7. Treatment

Children with IFS should be treated in a paediatric sarcoma centre. The aim is to cure the tumour while preserving function and appearance and avoiding long-term side effects (Orbach et al., 2020).

Surgery

If the tumour can be removed without harming important structures, surgery alone may be enough. A mutilating operation, such as amputation, is avoided whenever possible (Orbach et al., 2010; Sparber-Sauer et al., 2020).

Even when a small amount of tumour is left at the edges, the tumour often does not come back, so close follow-up may be chosen instead of further surgery.

TRK inhibitors

Drug Notes
Larotrectinib Oral liquid or capsule; very high response rates in NTRK-fusion tumours, including IFS (Laetsch et al., 2018; Hong et al., 2020)
Entrectinib Another TRK inhibitor approved for NTRK-fusion tumours
Newer TRK inhibitors Used in clinical trials if resistance develops

For tumours that cannot be removed safely, a TRK inhibitor is often the first treatment. Many tumours shrink dramatically within weeks, allowing a smaller operation or no operation at all. Doctors are still studying how long treatment should continue.

Chemotherapy

Situation Chemotherapy
No NTRK fusion, or TRK inhibitor not available Vincristine and actinomycin D (VA), a mild combination, works in many children
Tumours that do not respond Other combinations, such as those including ifosfamide or doxorubicin

Radiotherapy is rarely used in babies because of its long-term effects on growth. Chemotherapy is usually given as outpatient or short-stay treatment over several months, through a central line.

How the team chooses a treatment

The choice depends on a few key questions:

Question Why it matters
Can the tumour be removed without loss of function? If yes, surgery may be all that is needed
Does the tumour have an NTRK fusion? If yes, a TRK inhibitor is a strong option before or instead of surgery
Is the tumour bleeding or threatening breathing? Urgent treatment may be needed to control it quickly
How old is the baby and how well are they? Very young babies need careful drug dosing

If IFS is found before birth

When a tumour is seen on a pregnancy scan, a fetal medicine team plans the birth together with paediatric surgeons and oncologists. Delivery is usually arranged at a hospital with a neonatal intensive care unit. A caesarean section may be recommended for very large tumours to reduce the risk of bleeding during delivery. Treatment usually starts within the first days or weeks of life.

Side effects of treatment

Treatment Possible side effects
Larotrectinib Raised liver tests, low white cells, dizziness, weight gain and, rarely, bone fractures
Vincristine Constipation and nerve effects
Actinomycin D Low blood counts and liver effects
Surgery Scarring and possible effects on limb function

8. Outlook (prognosis)

The outlook is excellent. In the European experience, about 9 in 10 children survived long term, and spread to distant organs was rare (Orbach et al., 2010).

Factor Effect on outlook
Tumour completely removed Very good; low risk of recurrence
Response to TRK inhibitor or chemotherapy Most tumours respond well
Tumour in the trunk or head and neck Slightly higher risk of problems because surgery is harder
Distant spread Rare; usually to the lungs

Some tumours have even been reported to shrink on their own, but this cannot be relied on, so all babies are treated or closely monitored.

9. Follow-up and long-term effects

Follow-up Purpose
Regular check-ups and scans Detect any regrowth early; usually for several years
Growth and development checks Monitor the child’s progress
Physiotherapy Help with movement after limb surgery
Monitoring during TRK inhibitor treatment Blood tests and growth checks

10. Living with infantile fibrosarcoma

  • Ask for a specialist nurse as your main contact
  • Ask about TRK testing if it has not been done
  • Ask how to give oral medicines to a baby, and what to do if a dose is vomited
  • Look after yourself; caring for a sick baby is exhausting
  • Seek support from children’s cancer charities and parent groups
  • Plan feeding and development support with health visitors and physiotherapists
  • Keep a simple diary of medicine doses, feeds, weight and any bleeding from the lump
  • Take photographs of the lump at regular intervals if your team asks, as they can help to track changes between visits
  • Ask about travel and childcare advice during treatment, including when it is safe to attend nursery

11. Frequently asked questions

Question Answer
Is infantile fibrosarcoma cancer? It is a sarcoma, but it behaves much less aggressively than adult sarcomas and rarely spreads
Will my baby need an amputation? Very rarely; modern treatment aims to avoid this
What does larotrectinib do? It blocks the TRK fusion protein that drives the tumour
Can it come back? It can, mainly at the original site, but recurrences are usually treatable
Will my baby develop normally? Most children grow and develop normally after treatment
Was it caused by something in pregnancy? No
Can my baby have routine vaccines? Usually yes, but timing may change during chemotherapy; ask your team
Is it the same as a birthmark? No. It can look like a vascular birthmark, but it is a solid tumour that needs a biopsy

12. Questions to ask your care team

  • Has the tumour been tested for an NTRK fusion?
  • Can the tumour be removed safely, or should we start with a drug?
  • How long will treatment last?
  • What side effects should we watch for at home?
  • How will the treatment affect my child’s movement and growth?
  • How often will my child need scans?

Resources

  1. Davis, J.L. et al. (2022) ‘Mesenchymal neoplasms with NTRK and other kinase gene alterations’, Histopathology, 80(1), pp. 4-18.
  2. Hong, D.S. et al. (2020) ‘Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials’, Lancet Oncology, 21(4), pp. 531-540.
  3. Knezevich, S.R. et al. (1998a) ‘A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma’, Nature Genetics, 18(2), pp. 184-187.
  4. Knezevich, S.R. et al. (1998b) ‘ETV6-NTRK3 gene fusions and trisomy 11 establish a histogenetic link between mesoblastic nephroma and congenital fibrosarcoma’, Cancer Research, 58(22), pp. 5046-5048.
  5. Laetsch, T.W. et al. (2018) ‘Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study’, Lancet Oncology, 19(5), pp. 705-714.
  6. Orbach, D. et al. (2010) ‘Infantile fibrosarcoma: management based on the European experience’, Journal of Clinical Oncology, 28(2), pp. 318-323.
  7. Orbach, D. et al. (2020) ‘Spotlight on the treatment of infantile fibrosarcoma in the era of neurotrophic tropomyosin receptor kinase inhibitors: international consensus and remaining controversies’, European Journal of Cancer, 137, pp. 183-192.
  8. Sparber-Sauer, M. et al. (2020) ‘The impact of local control in the treatment of children with advanced infantile and adult-type fibrosarcoma: experience of the Cooperative Weichteilsarkom Studiengruppe (CWS)’, Journal of Pediatric Surgery, 55(9), pp. 1740-1747.
  9. National Cancer Institute (2026) Childhood Soft Tissue Sarcoma Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/soft-tissue-sarcoma/hp/child-soft-tissue-treatment-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.